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ABSTRACT
Objective: To synthesize inclusion complexes of oral antidiabetic drugs, i.e., Glipizide (GP) and Gliclazide (Glc) with a-cyclodextrin (α-CD) and varying 
the pH which will enhance the solubility and thereby oral bioavailability of the drugs.
Methods: Liquid inclusion complexes were prepared and characterized by ultraviolet-visible (UV-VIS) spectroscopic studies, and fluorescent studies 
solid inclusion complexes of GP and Glc with α-CD were prepared by co-evaporation method and characterized by differential scanning calorimetric 
studies (DSC) and1H nuclear magnetic resonance spectroscopic studies (1H NMR).
Results: The inclusion complexes of both GP and Glc with α-CD showed high binding constant values for pH 2 from the UV-VIS spectroscopy studies 
and fluorescent studies. DSC and1H NMR spectroscopic studies confirmed the inclusion of GP and Glc inside the α-CD cavity.
Conclusion: Formed with more stable inclusion complexes, with α-CD are GP and Glc at pH 2, along with pH modulation could be a suitable strategy 
to enhance the solubility and oral bioavailability of both the drugs.
Keywords: Solubility, Bioavailability, Glipizide, Gliclazide, Inclusion complexes, α-Cyclodextrin.
INTRODUCTION
Poor solubility and oral bioavailability are the two great challenges 
in the pharmaceutical industry. Poor aqueous solubility hinders the 
in vivo efficacy of the drugs due to low bioavailability, abnormal pharma 
kinetic profile, intersubject, interspecies variation [1] and thus poses 
challenging problems in the oral formulation development process.
Glipizide (GP), IUPAC name is 1-cyclohexyl-3-[[P-[2-(5-
methylpyrazinecarboxamido) ethyl] phenyl]-sulfonyl] urea, 
Gliclazide (Glc) IUPAC name is 1-[4methylbenzene)sulfonyl]-3-
octahydrocyclopenta[C] pyrrol-2-yl] urea.
GP and Glc are both second generation sulfonylurea hyperglycemic 
agents which are widely used in the treatment of noninsulin-dependent 
diabetes mellitus [2]. Both GP and Glc have very poor aqueous solubility 
and hence low bioavailability. Consequently, several studies have been 
developed for enhancement of solubility and bioavailability of GP and 
Glc through cyclodextrin (CD) inclusion complexes [3-7].
Enhancement in the solubility and the dissolution rate of such drugs can 
improve the oral bioavailability, which further improves the therapeutic 
efficacy and patient compliance. Different techniques have been used to 
improve the solubility and dissolution rate of the poorly soluble drugs, and 
in middle of the alternatives, the use of CD complexation presented a great 
interest [8] in recent years. CDs are cyclic oligosaccharides composed of 
glucopyranose units and can be represented as a truncated cone structure 
with a hydrophobic cavity. The hydrophobic cavity forms inclusion 
compounds with a wide range of guest molecules. Inclusion complex 
formation will modify the physicochemical properties such as solubility, 
stability, and bioavailability of poorly water-soluble drugs [9].
It is also a well-known fact that the pH of the medium is one of the 
important factors affecting the solubility of the drugs [10]. Hence, the 
present study is to investigate the effect of pH, in selected CD, i.e., α-CD 
complexation on the solubility of GP and Glc. The solubility study is 
carried out in different media, i.e., pH 2 and 7 to identify the physiological 
pH at which the drugs have the highest solubility and also the influence 
of α-CD complexation in enhancing the solubility of GP and Glc.
METHODS
Reagents and materials
Analytical grade of GP, Glc, and α-CD from Sigma-Aldrich were used for 
the studies. The solvents used were of analytical grade. Triply distilled 
water was used for the preparation of stock solutions.
Instruments
i. Systronics Smart Double beam Spectrophotometer-2203
ii. JASCO Spectrofluorometer FP-8200
iii. NETZSCH DSC 204 Calorimeter
iv. Bruker 300 MHz FT NMR Spectrometer.
Preparation of liquid inclusion complexes
About 0.0089 of GP was accurately weighed and dissolved in 10 ml 
solution maintained at pH 2 and 7. Similarly, 0.0064 g of Glc was 
weighed and dissolved in 10 ml solution maintained at pH 2 and pH 7. 
About 0.2918 g of α-CD was weighed and dissolved in 30 ml distilled 
water. Inclusion complexes were prepared by varying the concentration 
of α-CD from 2×10−3 M to 1×10−2 M with both the drugs. The reactions 
were carried out at room temperature (303 K).
Preparation of solid inclusion complexes
Solid inclusion complexes of GP and Glc with α-CD were prepared by 
co-evaporation method.
Differential scanning calorimetry (DSC)
DSC measurements were performed on an NETZSCH DSC 204 
calorimeter. Samples of 1-4 mg were accurately weighed in aluminum 
pans. These samples were then heated over a range of 25°C-300°C at a 
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constant rate of 10°C/minutes in a nitrogen purge of 50 ml/minutes. An 
empty aluminum pan was used as reference.
1H nuclear magnetic resonance (1H-NMR) spectroscopy
1H-NMR spectroscopy studies were carried out using Bruker 300MHz 
FT NMR Spectrometer. Chemical shifts were reported in ppm (δ) 
downfield from tetramethylsilane (internal reference 0 ppm). Samples 




From Fig. 2a, it was observed that at pH 2, the absorption spectrum of 
GP was obtained at 230.8 nm in the absence of α-CD. After the addition 
of α-CD, there is a bathochromic shift from lmax 230.8 to 241.3 nm. The 
absorption spectrum showed a hypsochromic shift from lmax 235.5 to 
229.5 nm as depicted in Fig. 2b. The spectral shifts were characteristic 
of the inclusion complexes formed by the encapsulation of the GP drug 
within the α-CD cavity.
For Glc, the absorption spectrum showed a bathochromic shift of lmax 
225.9-235.7 nm indicating the inclusion complex formation at pH 2 as 
shown in Fig. 3a. A hypsochromic shift was observed with a lmax from 
228.7 to 218.5 nm at pH 7 shown in Fig. 3b. The spectral shifts indicated 
the inclusion complex formation.
From Table 1, it was found that as the pH increases the intensity of 
absorption increases. The wavelength was shifted hypsochromically. 
After the addition of α-CD, a bathochromic shift was observed at pH 2, 
and a hypsochromic shift was observed at pH 7. This shows that as the 
pH of the medium increases, the solubility of both the drugs GP and Glc 
decreases.
Fluorescent studies
The fluorescent spectrum for GP α-CD complex exhibited a bathochromic 
shift of lmax 348- 371 nm at pH 2 shown in Fig. 4a. As the pH was increased 
to 7, a hypsochromic shift was observed from lmax 387 to 369 nm as 
shown in Fig. 4b. The spectral shifts were indicative of encapsulation 
of the GP within the α-CD cavity leading to the formation of inclusion 
complexes.
Fig. 3: Absorption spectrum of Gliclazide-α-cyclodextrin at (a) pH 2 and (b) pH 7
ba
Fig. 2: Absorption spectrum of Glipizide-α-cyclodextrin at (a) pH 2 and (b) pH 7. ABS: Absorbance
ba
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For Glc, a bathochromic shift was observed at pH 2 from lmax 393 to 
407 nm shown in Fig. 5a. At pH 7, a bathochromic shift was observed 
from lmax 388 to 392 nm shown in Fig. 5b. The spectral shifts were 
characteristic of the inclusion complex formation between Glc and 
α-CD.
From Table 2, it was observed that, as the pH increases the intensity of 
emission decreases, the wavelength was shifted hypsochromically for 
GP α-CD complexes. For Glc α-CD complex, a bathochromic shift was 
observed with decrease in intensity. This depicted that as the pH of the 
medium increases the solubility of both GP and Glc decreases.
The α-CD dependence of GP on absorption can be analyzed by the 
Benesi-Hildebrand plot as given by [11]:
1 1 1




− −' ( ' )[ ]
 (1)
Where, [α-CD] represents the concentration of α-CD and A0, A are the 
absorbances in the absence and presence of α-CD, respectively, and KB 
is the binding constant.
From Fig 6a and 7a, it was observed that a reciprocal graph of 
1
0A A−  
versus 
1
[ ] −CD  yielded a straight line which indicated the formation of 







 yielded a curve which indicated the 
formation of Glc-α-CD inclusion complex with 1:2 stoichiometry.
Similarly, the α-CD dependence on the fluorescent spectra of GP could 
be analyzed by the Benesi-Hildebrand plot as given by:
1 1 1




− −' ( ' )[ ]  (2)
Where, [α-CD] represents the concentration of α-CD and I0, I are the 
intensities of fluorescence in the absence and presence of α-CD, respectively.





 yielded a straight line which indicated the 
formation of GP-α-CD inclusion complex with 1:1 and 1:2 stoichiometry. 
Table 1: The absorption spectral data of Glipizide and Gliclazide inclusion complexes at pH 2 and 7
Drugs pH 2 pH 7







Glipizide 0 230.8 0.430 4.04 235.5 0.302 3.88
0.002 235.0 0.273 6.36 3.84 234.5 0.335 30.30 3.93 500
0.004 236.4 0.209 4.52 3.72 233.5 0.343 24.39 3.94 250
0.006 237.1 0.155 3.63 3.59 232.5 0.379 12.98 3.98 166.6
0.008 239.3 0.117 3.19 3.47 231.5 0.385 12.04 3.99 125
0.010 241.3 0.055 2.66 3.14 229.5 0.404 9.8 4.01 100
Gliclazide 0 225.9 0.103 3.43 228.7 0.096 3.40
0.002 227.3 0.132 34.48 3.54 226.6 0.132 27.7 3.54 500
0.004 228.9 0.155 19.23 3.61 223.4 0.146 20.00 3.58 250
0.006 229.1 0.164 16.39 3.63 221.0 0.171 13.33 3.65 166.6
0.008 232.0 0.187 11.90 3.69 219.7 0.209 8.84 3.74 125
0.10 235.7 0.262 6.289 3.83 218.5 0.226 7.69 3.77 100
Concn.: Concentration, Abs: Absorbance, Int: Intensity. A0: Absorbance of pure Glipizide/Gliclazide, A: Absorbance after addition of α-CD, [α-CD]: Concentration of a-CD, 
CD: Cyclodextrin
Fig. 5: Fluorescent spectrum of Gliclazide-α-cyclodextrin at (a) pH 2 and (b) pH 7
ba
Fig. 4: Fluorescent spectrum of Glipizide-α-cyclodextrin at (a) pH 2 and (b) pH 7
ba
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 yielded a straight line 
which indicated the formation of Glc α-CD inclusion complex with 1:2 
stoichiometry.
A linear relation is obtained in the case of absorption and fluorescence 
at both pH values for GP and Glc which revealed the stoichiometry of 
the complex formed by the GP with α-CD is 1:1,1:2 and that of Glc with 
α-CD is 1:2. Moreover, the linearity relation also indicated the increase 
in aqueous solubility of the drug upon complexation with increase in 
the concentration of α-CD.
The binding constant for GP α-CD complex from absorption studies 
was found to be 266/M at pH 2 and 245/M at pH 7. From fluorescent 
studies, it was evaluated as 276/M at pH 2 and 80.97/M at pH 7.
For Glc α-CD complexes, the binding constant was calculated to be 
117.5/M at pH 2 and 85.47 at pH 7 from absorption studies. Fluorescent 
studies showed that the binding constant was 112.0/M at pH 2 and 
84.1/M at pH 7.
As the value of binding constant increases, the stability of 
the inclusion complex also increases and hence the solubility 
of the drug increases. It was found that the value of binding 
constants decreases with increase in pH from 2 to 7. So, with 
increase in pH, the stability of the inclusion complexes formed 
between GP and Glc with α-CD and hence the solubility of both GP 
and Glc decreases.
DSC studies
DSC analysis was performed to characterize inclusion complexes with 
α-CD by comparing the thermal behavior of the individual components 
as well as their individual components [12-14].
When the guest molecules are incorporated into the CD cavity or in 
the crystal lattice, their melting point and boiling point usually shift 
to different temperatures or disappear within the temperature range 
Table 2: The fluorescent spectral data of Glipizide and Gliclazide inclusion complexes at pH 2 and pH 7
Drugs pH 2 pH 7





Glipizide 0 348 12.46 387 38.64
0.002 349 14.54 0.480 385 28.32 0.0968 500
0.004 354 17.08 0.216 380 19.14 0.0534 250
0.006 361 21.11 0.115 378 10.15 0.0351 166.6
0.008 368 23.4 0.091 373 8.86 0.0333 125
0.010 371 25.7 0.071 369 4.2 0.0290 100
Gliclazide 0 393 20.03 388 29.4
0.002 395 23.7 0.2724 389 26.0 0.2941 500
0.004 398 24.4 0.2288 390 24.7 0.2127 250
0.006 401 27.8 0.1287 391 22.9 0.1538 166.6
0.008 404 29.7 0.1034 392 20.1 0.1075 125
0.10 407 31.0 0.0911 392 18.9 0.0952 100
lflu: Wavelength of fluorescence, Int.: Intensity, I0: Intensity of drug without α-CD, I: Intensity after addition of a-CD, [α-CD]: Concentration of a-CD, CD: Cyclodextrin
Fig. 7: Benesi Hildebrand plot of (a) Glipizide-α-cyclodextrin (CD) at pH 2 and 7 (b) Gliclazide-α-CD at pH 2 and pH 7
ba
Fig. 6: Benesi Hildebrand plot of (a) Glipizide-α-cyclodextrin (CD) at pH 2 and 7 (b) Gliclazide-α-CD at pH 2 and pH 7
ba
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when CD lattice is decomposed. This is one of the best method for 
detecting drug-CD complexation [15].
The DSC thermograms of α-CD showed three exothermic peaks at 
72.5°C, 106.1°C, and 119.9°C which correspond to the dehydration of 
α-CD (Fig. 8a). Further, the thermogram was broadened indicative of the 
decomposition of α-CD and transition from crystallinity to amorphous 
nature. The DSC thermogram of GP showed one sharp characteristic 
exothermic peak at 216.4°C and 10.4°C corresponding to its melting 
point (Fig. 8b). However, in the case of the GP α-CD thermograms, 
three exothermic peaks were observed at 64.3°C, 97.2°C, and 140.4°C 
corresponding to the polymorphs formed during the fusion process via 
the dehydration of α-CD. The peak corresponding to the melting point 
of GP became extinct or disappeared in the DSC thermogram (Fig. 8c). 
Fig 8: Differential scanning calorimetric thermograms of (a) α-cyclodextrin (CD) (b) Glipizide (c) Glipizide α-CD (d) Gliclazide and 
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The extinction or disappearance of the exothermic peak of GP in GP 
α-CD thermogram was strong evidence for the total encapsulation 
of the GP in the α-CD cavity. This also suggested the formation of 1:1 
stoichiometry of inclusion complex between α-CD and GP.
The DSC thermograms of Glc showed a sharp characteristic exothermic 
peak at 167.2°C corresponding to its melting point (Fig. 8d). The 
broad peak around 40°C-80°C is due to the amorphous nature of Glc. 
The DSC thermogram of Glc α-CD complex indicated the characteristic 
exothermic peaks found in α-CD, i.e., at 72.6°C, 105.1°C, and 117.2°C 
due to the dehydration of α-CD (Fig. 8e).
Moreover, there is a shift of the exothermic peak characteristic of Glc 
from 167.2°C to 165.8°C, toward lower temperature. This is indicative 
of the partial encapsulation of the Glc drug in the α-cyclodextrn cavity. 
Hence, the inclusion complex formed is not of type 1:1. Instead, the 
stoichiometry was found to be 1:2.
NMR spectroscopic studies
The most direct evidence for the inclusion of a guest molecule into a CD 
cavity is obtained by 1H-NMR spectroscopy [16,17]. 1H-NMR may also 
be used to determine the direction of penetration of guest molecule 
into the CD cavity [18,19]. The H-3 and H-5 protons of CD which are 
directed toward the interior of the CD will show a significant upfield 
shift if inclusion does indeed occur and the H-1, H-2, and H-4 protons 
located at the exterior of the cavity will show marginal upfield shift. The 
spectrum of the guest molecule may also be changed upon inclusion 
complex formation [20,21].
The 1H-NMR chemical shift for each proton of α-CD was evaluated for 
the formation of inclusion complex between GP and α-CD.
The formation of inclusion complexes was studied by the changes in the 
chemical shifts caused by the guest and the host to each other [22-24]. 
In the structure of α-CD, H-3 and H-5 protons are located inside the 
cavity, H-3, H-5 located near the wider rim, and H-5 located at the 
narrow rim of the CD cavity. All other protons H-1, H-2, and H-4 are 
located on the exterior of the cavity.
From the Table 3, ∆δH-3=∆δH-5=−0.17<0, for the GP–α-CD complex. 
This showed that inclusion or encapsulation of GP inside the α-CD 
cavity took place, and an upfield was observed in the inclusion complex 
due to the dissolution of GP inside the α-CD cavity.
Further, the spectrum of pure GP was varied in the case of GP α-CD 
complex. This proved as a strong evidence for the inclusion complex 
formation.
The observed shielding effect can be attributed to the diamagnetic 
anisotropy effect due to the inclusion of a group rich in π electrons 
(aromatic ring) into the hydrophobic central cavity of α-CD molecule.
From Table 4, it was observed ∆δ H-3>∆δ H-5>0, which indicated 
encapsulation of the drug Glc in the α-CD cavity took place. The upfield 
shift observed in Glc α-CD inclusion complex was due to the dissolution 
of Glc drug inside the α-CD cavity and are shielded by the H-3 and H-5 
protons of α-CD.
Comparative study of the effect of pH on Glipizide and Gliclazide 
α-CD inclusion complexes
From the absorption and fluorescent studies, it was observed that 
the binding constant values were higher at pH 2 for both GP and 
Glc α-CD inclusion complexes. Ionized species were present at pH 2 
in both the complexes. However, it may be assumed that the ionic 
species were sufficiently far away from the hydrophobic cavity of 
the α-CD. The binding constant values of GP and Glc α-CD complexes 
were comparatively lower at pH 7. This phenomenon was exhibited 
by both the drugs because of the sulphonylurea group present in 
both the drug. The other groups do not interfere much with inclusion 
complex formation. Increase in pH of the medium decreases the 
stability of the inclusion complexes formed and hence the solubility 
of both GP and Glc. Therefore, it was evident that the most favorable 
pH for increasing the solubility of the drugs was at pH 2 and less 
favorable pH was 7. It was often assured that the unionized species 
were primarily responsible for the formation of the complex and 
subsequent increase in solubility. However, ionization of a drug can 
also result in enhanced complexation, and the solubility of the ionized 
drug complex can sometimes exceed the solubility of the unionized 
drug complex α-CD plays an important role in the solubility of GP and 
Glc together with pH adjustment. The solubility of the corresponding 
complexes can be much higher than what could be expected by 
increasing the total drug solubility through only appropriate pH 
adjustment. This is possible due is the specific interaction of the 
drugs molecules with the hydrogen bond system of the α-CD and/
or the modification of the hydrogen bounding network of the 
surrounding water molecules, the drugs can be strongly bound inside 
the α-CD cavity, even when they are in ionized form because their 
basic center, and hence, the charge can be located quite far away from 
the molecules hydrophobic part that is included in the α-CD cavity so 
that the complexation ability is not significantly compromised.
CONCLUSION
The absorption and fluorescent spectral studies confirmed the 
formation of α-CD inclusion complexes with both GP and Glc. From 
absorption and fluorescent studies, stoichiometry of GP α-CD complex 
is 1:1, 1:2 and that of Glc α-CD complex is 1:2. 1H NMR and DSC studies 
also served as evidence for the formation of inclusion complexes. The 
soluble and stable complexes were formed at pH value 2. The present 
study has demonstrated the possibility to improve the aqueous 
solubility of GP and Glc by simultaneous α-CD complexation and pH 
value modulation. High stability constant values were obtained only 
at pH 2 rather than pH 7. This has suggested that α-CD complexation 
accompanied with pH value modulation may be a suitable strategy to 
enhance the aqueous solubility of both GP and Glc, thus overcoming 
the problems associated with low bioavailability in the pharmaceutical 
formulation of both the drugs.
Table 3: 1H-chemical shifts (ppm) of the protons of 
α-cyclodextrin and Glipizide in the free and inclusion complex 
states
Proton α-CD δ0 (free) α-CD δC (complex) 
Glipizide-α-CD
Δδ (δC-δ0)
H-1 4.98 4.97 −0.01
H-2 3.63 3.62 −0.01
H-3 3.82 3.99 −0.17
H-4 3.40 3.77 −0.03
H-5 3.75 3.58 −0.17
H-6 3.92 3.89 −0.03
δ0: Chemical shift of pure α-CD, δC: Chemical shift of Glipizide α-CD complex,  
Δδ: Difference in chemical shift between complex and pure a-CD. CD: Cyclodextrin
Table 4: 1H-NMR chemical shifts (ppm) of the protons of α-CD 
and Gliclazide in the free and inclusion complex states
Protons α-CD δ0 (free) α-CD δc Gliclazide α-CD ∆δ=δc-δ0
H-1 4.98 - -
H-2 3.63 3.27 −0.36
H-3 3.96 2.78 −1.18
H-4 3.40 2.62 −0.78
H-5 3.78 2.47 −1.31
H-6 3.92 2.33 −1.59
δ0: Chemical shift of pure α-CD, δC: Chemical shift of Gliclazide α-CD complex,  
Δδ: Difference in chemical shift between complex and pure α-CD. CD: Cyclodextrin
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